This study focuses on psoriatic arthritis, a condition that causes joint pain and inflammation in people who have psoriasis. The study will test a new medication called sonelokimab, which is given as a subcutaneous injection under the skin. This medicine works by blocking specific proteins in the body that cause inflammation.
The purpose of this research is to determine how well sonelokimab works compared to placebo in treating people with active psoriatic arthritis who have not previously used biological medications. The study will compare two different ways of giving sonelokimab against placebo treatment.
Participants will receive either sonelokimab injections or placebo for 16 weeks. The medication dose will be 60 milligrams, given every four weeks. Throughout the study, doctors will monitor the participants’ symptoms, particularly focusing on how their joint pain and inflammation respond to the treatment. The study will also track any changes in participants’ ability to perform daily activities and their overall well-being.
1Initial visit and assessment
You will undergo initial assessment to confirm your eligibility for the study if you have psoriatic arthritis for at least 6 months
Your doctor will verify that you have at least 3 tender joints and 3 swollen joints
You must have at least one psoriatic plaque of 2 cm or more, or nail changes consistent with psoriasis
2Assignment to treatment group
You will be randomly assigned to one of three groups:
Group 1: Sonelokimab 60 mg with induction regimen
Group 2: Sonelokimab 60 mg without induction regimen
Group 3: Placebo (inactive substance)
3Treatment administration
You will receive subcutaneous injections (under the skin)
The treatment will be given every 4 weeks
The study will continue for at least 16 weeks to evaluate the primary results
4Monitoring and assessment
Regular evaluations will check your joint pain and swelling
Your psoriasis symptoms will be monitored
Blood tests and other safety assessments will be performed
Your ability to perform daily activities will be evaluated
X-rays will be taken to check joint damage
5Final assessment
At week 16, your response to treatment will be evaluated
The main measurement will be a 50% improvement in arthritis symptoms (ACR50)
Your psoriasis improvement will be assessed if you had skin involvement at the start
Overall health status and quality of life measurements will be taken
Who Can Join the Study?
Must be at least 18 years old
Must have confirmed psoriatic arthritis with symptoms present for at least 6 months
Must have moderate to severe active disease with at least 3 tender joints and 3 swollen joints
Must have active plaque psoriasis with at least one psoriatic patch of 2 cm or larger, or nail changes from psoriasis, or documented history of plaque psoriasis
Must test negative for rheumatoid factor and anti-cyclic citrullinated peptide (proteins found in blood that can indicate certain types of arthritis)
Must have been taking stable doses of anti-inflammatory medications (NSAIDs) for at least 4 weeks with inadequate symptom control, or have documented inability to take these medications
Must have tried at least one conventional disease-modifying medication (such as methotrexate, sulfasalazine, or leflunomide) for at least 12 weeks with inadequate response, or have documented inability to take these medications
Must have at least one bone erosion on hand and feet X-rays OR elevated levels of C-reactive protein (a marker of inflammation in blood)
Women who can become pregnant must use effective birth control during the study and for 8 weeks after the last treatment
Men must use condoms when sexually active with partners who can become pregnant during the study and for 8 weeks after the last treatment, unless surgically sterile
Must be able to follow the study protocol and schedule
Must be able to understand and sign informed consent documents
Who Cannot Join the Study?
Age below 18 or above 75 years old
Previous treatment with sonelokimab (the study medication)
Known allergic reactions to biological medications
Active or chronic infections, including tuberculosis and hepatitis B or C
History of cancer within the past 5 years (except successfully treated non-melanoma skin cancer)
Pregnant or breastfeeding women
Significant heart problems or uncontrolled high blood pressure
Severe kidney or liver disease
Other inflammatory arthritis conditions besides psoriatic arthritis
Major surgery planned during the study period
Participation in another clinical trial within 30 days before this study
Active substance abuse or mental health conditions that could interfere with study participation
Use of prohibited medications, including certain immunosuppressive drugs (medications that weaken the immune system)
Unstable psoriatic arthritis requiring immediate change in treatment
Live vaccines received within 12 weeks before starting the study
Sonelokimab is a new biological medication that is being studied for treating psoriatic arthritis. It is given as an injection under the skin (subcutaneously) to patients who have never received biological disease-modifying antirheumatic drugs (DMARDs) before. This medication works by targeting specific components of the immune system that are involved in causing joint inflammation and skin symptoms in psoriatic arthritis.
A Placebo is used in this study as a comparison treatment. It is an inactive substance that looks identical to the real medication but contains no active ingredients. This helps researchers determine how effective the actual medication is by comparing results between patients who receive the real medication and those who receive the placebo.
Psoriatic arthritis – A chronic inflammatory joint condition that typically develops in people who have psoriasis. The condition causes joint pain, stiffness, and swelling that can affect any part of the body, particularly the fingers, toes, wrists, ankles, and lower back. It often results in joints becoming tender and swollen, with some people experiencing reduced range of motion. The condition can vary in severity, with some people having mild symptoms while others experience more persistent joint problems. The inflammation can also affect surrounding tendons and ligaments, causing additional discomfort and reduced mobility.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Bulgaria 
Croatia 
Czechia 
Estonia 
Finland 
France 
Germany 
Greece 
Hungary 
Latvia 
Lithuania 
Poland 
Portugal 
Romania 
Slovakia 
Spain